Chronic Graft-versus-Host Disease Clinical Trials

Chronic GVHD is driven by donor T cells and B cells that recognize recipient tissue antigens, initiating a multi-phase immune response involving both alloreactive immunity and aberrant immune reconstitution. The pathophysiology involves thymic damage (preventing normal tolerance mechanisms), B-cell dysregulation with autoantibody production, tissue fibrosis mediated by transforming growth factor beta and platelet-derived growth factor pathways, and macrophage-driven inflammation. The disease is graded as mild, moderate, or severe based on the NIH Consensus Criteria, which assess the number of organs involved, the severity of involvement in each organ, and the functional impact.

The most common symptoms of Chronic Graft-versus-Host Disease include Skin rashes, thickening, tightening, or discoloration resembling scleroderma, Severe dry mouth, mouth sores, and difficulty eating, Dry, irritated eyes and light sensitivity, Shortness of breath from bronchiolitis obliterans (irreversible airway scarring), Liver dysfunction with elevated bilirubin and liver enzymes, among others. Affects 30 to 70% of patients who receive allogeneic hematopoietic stem cell transplant; approximately 14,000 new cases annually in the U.S.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Chronic Graft-versus-Host Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. If you have been diagnosed with chronic GVHD that is not responding to corticosteroids, 4 FDA-approved therapies are now available, each with a different mechanism. Ibrutinib is approved after 1 or more earlier treatments (ages 1 and up) and ruxolitinib after 1 or 2 (ages 12 and up), while belumosudil (ages 12 and up) and axatilimab (at least 40 kg body weight) are approved after 2 or more.

Yes. As of October 14, 2026, 4 FDA-approved medicines have a current label that names Chronic Graft-versus-Host Disease: Imbruvica (ibrutinib), first approved in 2017; Jakafi (ruxolitinib), first approved in 2021; Niktimvo (axatilimab), first approved in 2024; and Rezurock (belumosudil), first approved in 2021. Corticosteroids and immune globulins count once each.

Chronic Graft-versus-Host Disease is an acquired condition, not an inherited one. Caused by donor T cells reacting against recipient tissue after allogeneic transplant; risk rises with HLA mismatch, but there is no diagnostic genetic test for the disease itself. Affects 30 to 70% of patients who receive allogeneic hematopoietic stem cell transplant; approximately 14,000 new cases annually in the U.S.

Eligibility for Chronic Graft-versus-Host Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Chronic Graft-versus-Host Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.